Healthcare Distribution Alliance – Patients Move Us.
Share Print


HDA Statement on Review of Annual Production Quotas for Opioids

March 2, 2018

ARLINGTON, Va. — HDA President and CEO John M. Gray released the following statement in response to Attorney General Jeff Sessions' recent memo regarding opioid production quotas.

“We welcome Attorney General Sessions’ call to evaluate potential changes to the annual production quotas for opioids. This critical step reflects the growing recognition of the federal government’s role in addressing this public health crisis. During the height of the opioid epidemic, the Drug Enforcement Administration (DEA) continually approved significant year-over-year increases in opioid production. In fact, between 1993 and 2015, the DEA approved a 39-fold increase of oxycodone, a 12-fold increase of hydrocodone and a 25-fold increase of fentanyl. While the agency’s recent focus on reducing the production of opioids is commendable, it raises the question as to why similar steps were not undertaken earlier. If we are going to effectively turn the tide with this public health emergency, then it requires real action to address the factors that contributed to the epidemic in the first place."

For more information on industry efforts to combat the opioid epidemic, click here.


The Healthcare Distribution Alliance (HDA) represents primary pharmaceutical distributors — the vital link between the nation’s pharmaceutical manufacturers and pharmacies, hospitals, long-term care facilities, clinics and others nationwide. Since 1876, HDA has helped members navigate regulations and innovations to get the right medicines to the right patients at the right time, safely and efficiently. The HDA Research Foundation, HDA’s nonprofit charitable foundation, serves the healthcare industry by providing research and education focused on priority healthcare supply chain issues.


© 2020 Healthcare Distribution Alliance. All rights reserved.
HDA: E | C | C2 | NF | O365